Search results for "ISCHEMIC-STROKE"

showing 9 items of 9 documents

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

Mean Platelet Volume and Arterial Stiffness - Clinical Relationship and Common Genetic Variability

2017

AbstractVessel wall stiffening is an important clinical parameter, but it is unknown whether platelets, key elements in the pathogenesis of arterial thrombosis, are associated with arterial stiffness. The present studies sought to determine whether mean platelet volume (MPV), a potential marker of platelet activation, is linked to vascular elasticity as assessed by the augmentation index (AIx), in 15,010 individuals from the population-based Gutenberg Health Study. Multivariable analysis showed that MPV in both males (β 0.776; 95thCI [0.250;1.16]; p = 0.0024) and females (β 0.881[0.328;1.43]; p = 0.0018) is strongly associated with AIx. Individuals with MPV and AIx above the sex-specific me…

Male0301 basic medicinemedicine.medical_specialtyPopulationKaplan-Meier Estimate030204 cardiovascular system & hematologyPolymorphism Single NucleotideArticle03 medical and health sciencesSex FactorsVascular Stiffness0302 clinical medicineGUTENBERG HEALTHDEFICIENTINFLAMMATIONRisk FactorsInternal medicinemedicineHumansPlateletPlatelet activationMean platelet volumeeducationMETAANALYSISeducation.field_of_studyMultidisciplinaryHYPERTENSIONbusiness.industryProportional hazards modelHazard ratioGenetic VariationCROSS-SECTIONAL RELATIONSmedicine.diseaseThrombosisElasticityREACTIVITY030104 developmental biologyISCHEMIC-STROKEATHEROSCLEROSISCardiovascular DiseasesArterial stiffnessCardiologyFemalebusinessMean Platelet VolumeVASCULAR FUNCTIONBiomarkers
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Homoarginine Levels are Regulated by L-Arginine: Glycine Amidinotransferase and Affect Stroke Outcome: Results from Human and Murine Studies

2013

Background— Endogenous arginine homologues, including homoarginine, have been identified as novel biomarkers for cardiovascular disease and outcomes. Our studies of human cohorts and a confirmatory murine model associated the arginine homologue homoarginine and its metabolism with stroke pathology and outcome. Methods and Results— Increasing homoarginine levels were independently associated with a reduction in all-cause mortality in patients with ischemic stroke (7.4 years of follow-up; hazard ratio for 1-SD homoarginine, 0.79 [95% confidence interval, 0.64–0.96]; P =0.019; n=389). Homoarginine was also independently associated with the National Institutes of Health Stroke Scale+age score …

Malegenetics [Homoarginine]AmidinotransferasesArginineGenome-wide association studyCohort StudiesMicesingle nucleotide polymorphismMedicinehomoarginineProspective StudiesStrokegenetics [Arginine]CARDIOVASCULAR RISKHazard ratioMOUSE MODELMiddle Ageddiagnosis [Stroke]strokeDEFICIENCYTreatment OutcomeISCHEMIC-STROKEgenetics [Stroke]genetics [Amidinotransferases]genetics [Polymorphism Single Nucleotide]FemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySingle-nucleotide polymorphismMASS-SPECTROMETRIC DETERMINATIONArginineGUANIDINO COMPOUNDSPhysiology (medical)Internal medicineglycine amidinotransferaseAnimalsHumansCREATINEddc:610Translational research Energy and redox metabolism [ONCOL 3]AgedNITRIC-OXIDEBLOOD-FLOWbusiness.industryVascular diseasemedicine.diseaseHomoarginineCEREBRAL-ARTERY OCCLUSIONL-arginine:glycine amidinotransferaseMice Inbred C57BLDisease Models AnimalEndocrinologyHEK293 CellsGlycinegenome-wide association studiesHuman medicineArginine:glycine amidinotransferasebusinessGenome-Wide Association StudyCirculation
researchProduct

''Circulating and Brain BDNF Levels in Stroke Rats. Relevance to Clinical Studies''

2011

International audience; ''Background: Whereas brain-derived neurotrophic factor (BDNF) levels are measured in the brain in animal models of stroke, neurotrophin levels in stroke patients are measured in plasma or serum samples. The present study was designed to investigate the meaning of circulating BDNF levels in stroke patients. Methods and Results: Unilateral ischemic stroke was induced in rats by the injection of various numbers of microspheres into the carotid circulation in order to mimic the different degrees of stroke severity observed in stroke patients. Blood was serially collected from the jugular vein before and after (4 h, 24 h and 8 d) embolization and the whole brains were co…

Malelcsh:MedicineEDEMA''CardiovascularBiochemistry0302 clinical medicineNeurotrophic factorsJugular veinEdemaBlood plasmaNeurobiology of Disease and RegenerationMedicineHippocampus (mythology)Plateletlcsh:ScienceStroke0303 health sciencesMultidisciplinary''NEUROTROPHIC FACTORbiologyBrainNeurochemistryAnimal ModelsRECOVERYDEPRESSIONPLATELETSStrokeISCHEMIC-STROKENeurologyOrgan SpecificityAnesthesia[ SCCO.NEUR ] Cognitive science/NeuroscienceMedicinemedicine.symptomNeurotrophinResearch Articlemedicine.medical_specialtyCerebrovascular DiseasesImmunologyMETABOLISM03 medical and health sciencesModel OrganismsInternal medicineAnimalsHumanscardiovascular diseasesRats WistarImmunoassaysBiology030304 developmental biologyIschemic Strokebusiness.industryBrain-Derived Neurotrophic Factor[SCCO.NEUR]Cognitive science/Neurosciencelcsh:REDEMAmedicine.diseaseENDOTHELIAL-CELLSRatsEndocrinologynervous systemMARKERbiology.proteinImmunologic TechniquesRatlcsh:QClinical Immunologybusiness030217 neurology & neurosurgeryNeuroscienceNEUROTROPHIC FACTOR
researchProduct

Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke

2016

Background and Purpose— We compared outcome and complications in patients with stroke treated with intravenous thrombolysis (IVT) who could not live alone without help of another person before stroke (dependent patients) versus independent ones. Methods— In a multicenter IVT-register–based cohort study, we compared previously dependent (prestroke modified Rankin Scale score, 3–5) versus independent (prestroke modified Rankin Scale score, 0–2) patients. Outcome measures were poor 3-month outcome (not reaching at least prestroke modified Rankin Scale [dependent patients]; modified Rankin Scale score of 3–6 [independent patients]), death, and symptomatic intracranial hemorrhage. Unadjusted an…

Malemedicine.medical_treatment030204 cardiovascular system & hematologylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawModified Rankin ScaleActivities of Daily Living80 and overThrombolytic TherapyRegistriesStrokeriskAged 80 and overpreexisting disabilityMedicine (all)survivorsThrombolysisMiddle Aged3. Good healthStrokeTreatment OutcomeInfusions intravenous; Intracranial hemorrhages; Outcome assessment (health care); Stroke; Survivors; Administration Intravenous; Aged; Aged 80 and over; Cohort Studies; Female; Humans; Logistic Models; Male; Middle Aged; Stroke; Treatment Outcome; Activities of Daily Living; Independent Living; Registries; Thrombolytic Therapy; Medicine (all); Neurology (clinical); Cardiology and Cardiovascular Medicine; Advanced and Specialized Nursingcontrolled-trialAdministration[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Administration IntravenousFemaleIndependent Livingacute ischemic-strokehemorrhageCardiology and Cardiovascular MedicineCohort studymedicine.medical_specialtyintracranial hemorrhagesstatinsscale03 medical and health sciencesInternal medicinemedicineHumansDementiaAgedoutcome assessment (health care)Advanced and Specialized Nursingreliabilitybusiness.industryOdds ratiomedicine.diseaseConfidence intervalinfusionsSurgeryLogistic Models[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]intravenousiv thrombolysisNeurology (clinical)business030217 neurology & neurosurgeryStroke
researchProduct

''Deferoxamine blocks death induced by glutathione depletion in PC 12 cells''

2013

Chouraqui, E. | Leon, A. | Repesse, Y. | Prigent-Tessier, A. | Bouhallab, S. | Bougle, D. | Marie, C. | Duval, D.; International audience; ''The purpose of the present work was to investigate the mechanisms by which glutathione depletion induced by treatment with buthionine sulfoximine (BSO) led within 24-30 h to PC 12 cells apoptosis. Our results showed that treatment by relatively low concentrations (10-30 mu M) of deferoxamine (DFx), a natural iron-specific chelator, almost completely shielded the cells from BSO-induced toxicity and that DFx still remained protective when added up to 9-12 h after BSO treatment. On the other hand, phosphopeptides derived from milk casein and known to carr…

Time FactorsIronApoptosisDeferoxaminePharmacologyIron Chelating AgentsToxicologymedicine.disease_causePC12 Cellschemistry.chemical_compoundOXIDATIVE-STRESSPARKINSONS-DISEASECaseinmedicineAnimalsHomeostasisButhionine sulfoximineButhionine SulfoximineNeuronsCELLULAR IRONDose-Response Relationship DrugbiologyChemistryGeneral NeuroscienceGlutathioneGlutathioneIRON CHELATORRatsDeferoxamineFerritinSYMPATHETIC NEURONSISCHEMIC-STROKEBiochemistryBRAIN IRONCELLULAR IRON''CytoprotectionApoptosisToxicity[ SCCO.NEUR ] Cognitive science/Neurosciencebiology.proteinSERUM DEPRIVATIONHEME OXYGENASE-1NEURODEGENERATIVE DISORDERSOxidative stress''OXIDATIVE-STRESSmedicine.drug
researchProduct

Large-Scale Candidate Gene Analysis in Whites and African Americans Identifies IL6R Polymorphism in Relation to Atrial Fibrillation The National Hear…

2011

Background— The genetic background of atrial fibrillation (AF) in whites and African Americans is largely unknown. Genes in cardiovascular pathways have not been systematically investigated. Methods and Results— We examined a panel of approximately 50 000 common single-nucleotide polymorphisms (SNPs) in 2095 cardiovascular candidate genes and AF in 3 cohorts with participants of European (n=18 524; 2260 cases) or African American descent (n=3662; 263 cases) in the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource. Results in whites were followed up in the German Competence Network for AF (n=906, 468 cases). The top result was assessed in relation to incident i…

medicine.medical_specialtyCandidate geneINTERLEUKIN-6ATHEROSCLEROSIS RISKSingle-nucleotide polymorphismVARIANTSDISEASEINFLAMMATIONDESIGNsingle nucleotide polymorphismInternal medicinecohort studyGeneticsmedicineatrial fibrillationCHROMOSOME 4Q25Genetics (clinical)Geneticsbusiness.industryHazard ratioAtrial fibrillationrace/ethnicitymedicine.diseaseC-REACTIVE PROTEINEUROPEAN ANCESTRYISCHEMIC-STROKERelative riskCohortepidemiologyCardiology and Cardiovascular MedicinebusinessCandidate Gene AnalysisCohort study
researchProduct